Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 19769737)

1.

Harnessing CD1d-restricted T cells toward antitumor immunity in humans.

Neparidze N, Dhodapkar MV.

Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.

2.

Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.

Dhodapkar MV, Richter J.

Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12. Review.

3.

The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.

Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nakui M, Sekimoto M, Koda T.

Int Immunol. 2000 Jul;12(7):987-94.

4.

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.

Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I.

Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.

PMID:
24148970
5.

Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.

Dhodapkar MV.

Front Biosci (Landmark Ed). 2009 Jan 1;14:796-807. Review.

6.

Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice.

Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S.

J Clin Invest. 2011 Jan;121(1):249-64. doi: 10.1172/JCI43964. Epub 2010 Dec 13.

7.

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.

Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, Mazzarello A, Daga A, Corvò R, De Rossi G, Frassoni F, Ciccone E, Fais F.

Haematologica. 2009 Jul;94(7):967-74. doi: 10.3324/haematol.2008.001339. Epub 2009 May 19.

8.

CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.

Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, Lang ML.

Infect Immun. 2010 Apr;78(4):1610-7. doi: 10.1128/IAI.00002-10. Epub 2010 Feb 1.

9.

Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte.

Rhost S, Löfbom L, Rynmark BM, Pei B, Månsson JE, Teneberg S, Blomqvist M, Cardell SL.

Eur J Immunol. 2012 Nov;42(11):2851-60. doi: 10.1002/eji.201142350. Epub 2012 Aug 22.

PMID:
22777932
10.

CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.

Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, Besra GS, Bharadwaj M, Godfrey DI, McCluskey J, Rossjohn J.

Nature. 2007 Jul 5;448(7149):44-9. Epub 2007 Jun 20.

PMID:
17581592
11.

Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.

Fujii S, Shimizu K, Hemmi H, Steinman RM.

Immunol Rev. 2007 Dec;220:183-98. Review.

PMID:
17979847
12.

Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Webb TJ, Bieler JG, Schneck JP, Oelke M.

J Immunol Methods. 2009 Jul 31;346(1-2):38-44. doi: 10.1016/j.jim.2009.05.003. Epub 2009 May 14.

13.

Harnessing invariant NKT cells in vaccination strategies.

Cerundolo V, Silk JD, Masri SH, Salio M.

Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451. Review.

PMID:
19079136
14.

Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.

East JE, Sun W, Webb TJ.

J Vis Exp. 2012 Dec 29;(70). pii: 4333. doi: 10.3791/4333.

15.

Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.

Schiefner A, Fujio M, Wu D, Wong CH, Wilson IA.

J Mol Biol. 2009 Nov 20;394(1):71-82. doi: 10.1016/j.jmb.2009.08.061. Epub 2009 Sep 2.

16.

Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.

Pellicci DG, Patel O, Kjer-Nielsen L, Pang SS, Sullivan LC, Kyparissoudis K, Brooks AG, Reid HH, Gras S, Lucet IS, Koh R, Smyth MJ, Mallevaey T, Matsuda JL, Gapin L, McCluskey J, Godfrey DI, Rossjohn J.

Immunity. 2009 Jul 17;31(1):47-59. doi: 10.1016/j.immuni.2009.04.018.

17.

NKT and tolerance.

Diana J, Beaudoin L, Gautron AS, Lehuen A.

Methods Mol Biol. 2011;677:193-206. doi: 10.1007/978-1-60761-869-0_14.

PMID:
20941612
18.

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity.

Fujii S, Goto A, Shimizu K.

Blood. 2009 Apr 30;113(18):4262-72. doi: 10.1182/blood-2008-08-176446. Epub 2009 Jan 22.

19.

Differential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation.

Joshi SK, Lang GA, Devera TS, Johnson AM, Kovats S, Lang ML.

J Leukoc Biol. 2012 May;91(5):783-90. doi: 10.1189/jlb.1111559. Epub 2012 Feb 13.

20.

Role of γδ T cells in α-galactosylceramide-mediated immunity.

Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ.

J Immunol. 2012 Apr 15;188(8):3928-39. doi: 10.4049/jimmunol.1103582. Epub 2012 Mar 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk